AYTU BIOPHARMA, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
AYTU BIOPHARMA, INC (AYTU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-09-22
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2026 was 0.00 shares, a 100.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 87.50K shares, a 22.91% decline from fiscal 2024.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 113.50K shares, a 130.63% increase from fiscal 2023.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 49.21K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | 0.00 shares derived: sum of 2 quarters · filed 2026-09-22 | 0.00 shares derived: sum of 3 quarters · filed 2026-09-22 | 0.00 shares 10-K · filed 2026-09-22 |
| 2026-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-13 | 0.00 shares 10-Q · filed 2026-05-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | 0.00 shares 10-Q · filed 2026-02-03 | 0.00 shares derived: sum of 3 quarters · filed 2026-09-22 | 87.50K shares derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2026-09-22 | 87.50K shares derived: sum of 3 quarters · filed 2026-09-22 | 170.50K shares derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | 87.50K shares derived: sum of 2 quarters · filed 2026-09-22 | 170.50K shares derived: sum of 3 quarters · filed 2026-09-22 | 87.50K shares 10-K · filed 2026-09-22 |
| 2025-03-31 | 87.50K shares 10-Q · filed 2025-05-14 | 170.50K shares derived: sum of 2 quarters · filed 2025-05-14 | 87.50K shares 10-Q · filed 2025-05-14 | 170.50K shares derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-12-31 | 83.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | 83.00K shares 10-Q · filed 2025-02-12 | 83.00K shares derived: sum of 3 quarters · filed 2025-09-23 | 84.50K shares derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2025-09-23 | 1.50K shares derived: sum of 3 quarters · filed 2025-09-23 | 1.50K shares derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | 1.50K shares derived: sum of 2 quarters · filed 2025-09-23 | 1.50K shares derived: sum of 3 quarters · filed 2025-09-23 | 113.50K shares 10-K · filed 2025-09-23 |
| 2024-03-31 | 1.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | 1.50K shares derived: sum of 2 quarters · filed 2024-05-15 | 113.50K shares 10-Q · filed 2024-05-15 | 113.50K shares derived: sum of 4 quarters · filed 2024-09-26 |
| 2023-12-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | 112.00K shares 10-Q · filed 2024-02-14 | 112.00K shares derived: sum of 3 quarters · filed 2024-09-26 | 112.00K shares derived: sum of 4 quarters · filed 2024-09-26 |
| 2023-09-30 | 112.00K shares 10-Q · filed 2023-11-14 | 112.00K shares derived: sum of 2 quarters · filed 2024-09-26 | 112.00K shares derived: sum of 3 quarters · filed 2024-09-26 | |
| 2023-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | 0.00 shares derived: sum of 2 quarters · filed 2024-09-26 | 49.21K shares 10-K · filed 2024-09-26 | |
| 2023-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | 49.21K shares 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | 49.21K shares 10-Q · filed 2023-02-21 | |||
| 2022-06-30 | 0.00 shares 10-K · filed 2023-10-12 | |||
| 2021-06-30 | 69.72K shares 10-K · filed 2021-09-28 | |||
| 2021-03-31 | 69.72K shares 10-Q · filed 2021-05-17 | 69.72K shares derived: sum of 2 quarters · filed 2021-05-17 | ||
| 2020-12-31 | 0.00 shares 10-Q · filed 2021-05-17 | 0.00 shares 10-Q · filed 2021-02-11 | ||
| 2019-12-31 | 0.00 shares 10-Q · filed 2021-02-11 | 0.00 shares 10-Q · filed 2021-02-11 | ||
| 2017-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | 0.00 shares derived: sum of 2 quarters · filed 2017-05-11 | 442.00K shares 10-Q · filed 2017-05-11 | |
| 2016-12-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | 442.00K shares 10-Q · filed 2017-02-09 | ||
| 2016-09-30 | 442.00K shares 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |